Logo image of MRK

MERCK & CO. INC. (MRK) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:MRK - US58933Y1055 - Common Stock

110.53 USD
-0.46 (-0.41%)
Last: 1/9/2026, 9:42:39 PM
110.54 USD
+0.01 (+0.01%)
After Hours: 1/9/2026, 9:42:39 PM

MRK Key Statistics, Chart & Performance

Key Statistics
Market Cap274.34B
Revenue(TTM)64.23B
Net Income(TTM)19.03B
Shares2.48B
Float2.48B
52 Week High112.9
52 Week Low73.31
Yearly Dividend3.1
Dividend Yield3.06%
EPS(TTM)8.81
PE12.55
Fwd PE11.97
Earnings (Next)02-03 2026-02-03/amc
IPO1941-01-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


MRK short term performance overview.The bars show the price performance of MRK in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

MRK long term performance overview.The bars show the price performance of MRK in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10

The current stock price of MRK is 110.53 USD. In the past month the price increased by 13.22%. In the past year, price increased by 11.37%.

MERCK & CO. INC. / MRK Daily stock chart

MRK Latest News, Press Relases and Analysis

MRK Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.37 1.01T
JNJ JOHNSON & JOHNSON 19.69 492.44B
PFE PFIZER INC 7.96 144.87B
BMY BRISTOL-MYERS SQUIBB CO 8.52 113.72B
ZTS ZOETIS INC 20.06 56.04B
RPRX ROYALTY PHARMA PLC- CL A 9.77 23.19B
VTRS VIATRIS INC 5.48 14.70B
ELAN ELANCO ANIMAL HEALTH INC 24.45 11.66B
AXSM AXSOME THERAPEUTICS INC N/A 8.54B
BLTE BELITE BIO INC - ADR N/A 5.53B
CRNX CRINETICS PHARMACEUTICALS IN N/A 5.05B
AMRX AMNEAL PHARMACEUTICALS INC 17.28 4.07B

About MRK

Company Profile

MRK logo image Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Company Info

MERCK & CO. INC.

126 East Lincoln Avenue, P.O. Box 2000

Rahway NEW JERSEY 07033 US

CEO: Kenneth C. Frazier

Employees: 75000

MRK Company Website

MRK Investor Relations

Phone: 19087404000

MERCK & CO. INC. / MRK FAQ

What does MRK do?

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.


Can you provide the latest stock price for MERCK & CO. INC.?

The current stock price of MRK is 110.53 USD. The price decreased by -0.41% in the last trading session.


What is the dividend status of MERCK & CO. INC.?

MERCK & CO. INC. (MRK) has a dividend yield of 3.06%. The yearly dividend amount is currently 3.1.


How is the ChartMill rating for MERCK & CO. INC.?

MRK has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What is the analyst forecast for MRK stock?

34 analysts have analysed MRK and the average price target is 110.37 USD. This implies a price decrease of -0.15% is expected in the next year compared to the current price of 110.53.


How many employees does MERCK & CO. INC. have?

MERCK & CO. INC. (MRK) currently has 75000 employees.


What is the next earnings date for MRK stock?

MERCK & CO. INC. (MRK) will report earnings on 2026-02-03, after the market close.


MRK Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to MRK. When comparing the yearly performance of all stocks, MRK is one of the better performing stocks in the market, outperforming 78.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MRK Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to MRK. While MRK belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRK Financial Highlights

Over the last trailing twelve months MRK reported a non-GAAP Earnings per Share(EPS) of 8.81. The EPS increased by 48.07% compared to the year before.


Industry RankSector Rank
PM (TTM) 29.63%
ROA 14.69%
ROE 36.71%
Debt/Equity 0.77
Chartmill High Growth Momentum
EPS Q2Q%70.7%
Sales Q2Q%3.72%
EPS 1Y (TTM)48.07%
Revenue 1Y (TTM)1.68%

MRK Forecast & Estimates

34 analysts have analysed MRK and the average price target is 110.37 USD. This implies a price decrease of -0.15% is expected in the next year compared to the current price of 110.53.

For the next year, analysts expect an EPS growth of 18.62% and a revenue growth 1.24% for MRK


Analysts
Analysts77.06
Price Target110.37 (-0.14%)
EPS Next Y18.62%
Revenue Next Year1.24%

MRK Ownership

Ownership
Inst Owners80.32%
Ins Owners0.05%
Short Float %1.5%
Short Ratio2.67